CG Oncology, Inc. (NASDAQ: CGON) announced topline results from its Phase 3 PIVOT-006 registrational trial on November 16, 2026. The study evaluated adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC) following complete tumor resection. The company reported that the trial achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement over the control arm.
The data indicates that cretostimogene resulted in a 68% reduction in the risk of recurrence compared to the control arm. The hazard ratio was reported as 0.32, with a 95% confidence interval of 0.23 to 0.45 and a p-value of less than 0.0001. The median follow-up period for the study was 17 months as of October 26, 2026.
In terms of safety, the company stated that cretostimogene was generally well tolerated, with results consistent with previous studies. No Grade 3 or greater treatment-related adverse events (TRAEs) were reported, and there were no treatment-related discontinuations.
The company also provided an update on its regulatory timeline. Based on feedback from the U.S. Food and Drug Administration (FDA), the initial Biologics License Application (BLA) for cretostimogene in BCG-unresponsive NMIBC is expected to be broadened to include patients with high-grade papillary-only disease (without carcinoma in situ). The company anticipates completing this submission before the end of March 2027. Additionally, a BLA submission for the use of cretostimogene in intermediate-risk and high-grade Ta NMIBC is planned for the second quarter of 2027.